| |
| Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: gastric cancer |
| Chongqing T, Liubao P, Xiaohui Z, Jianhe L, Xiaomin W, Gannong C, Siying W, Lihui O, Ziying Z |
|
|
| |
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Chongqing T, Liubao P, Xiaohui Z, Jianhe L, Xiaomin W, Gannong C, Siying W, Lihui O, Ziying Z. Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: gastric cancer. PharmacoEconomics 2013: epub Indexing Status Subject indexing assigned by NLM MeSH Antineoplastic Combined Chemotherapy Protocols /administration & Capecitabine; Chemotherapy, Adjuvant /economics; Cost-Benefit Analysis; Deoxycytidine /administration & Disease-Free Survival; Fluorouracil /administration & Gastrectomy /economics; Humans; Markov Chains; Models, Molecular; Multicenter Studies as Topic; Organoplatinum Compounds /administration & Practice Guidelines as Topic; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Stomach Neoplasms /drug therapy /surgery; derivatives /economics /therapeutic use; derivatives /economics /therapeutic use; dosage /analogs & dosage /analogs & dosage /economics /therapeutic use; dosage /economics /therapeutic use AccessionNumber 22013022409 Date bibliographic record published 17/06/2013 |
| |
|
|
